Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPC | P11150 | 1/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.46 |
| ▸ | CRHR1 | P34998 | 17/20 | 0.41 |
| ▸ | GPR39 | O43194 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4621483 | 0.95 | LIPC (0.42) | LIPCLIPGCRHR1GPR39 | |
| SCHEMBL4621959 | 0.94 | LIPC (0.41) | LIPCLIPGCRHR1GPR39 | |
| SCHEMBL5916890 | 0.78 | CYP1A2 (0.41) | — | |
| SCHEMBL4620138 | 0.75 | LMNA (0.40) | — | |
| SCHEMBL5916942 | 0.74 | TRPV1 (0.60) | LIPCLIPGCRHR1GPR39 | |
| SCHEMBL5917026 | 0.74 | TRPV1 (0.49) | LIPCLIPGCRHR1GPR39 | |
| SCHEMBL4618878 | 0.74 | TRPV1 (0.51) | LIPCLIPGCRHR1GPR39 | |
| SCHEMBL5917081 | 0.74 | TRPV1 (0.60) | LIPCLIPGCRHR1GPR39 | |
| SCHEMBL5916919 | 0.74 | TRPV1 (0.60) | LIPCLIPGCRHR1GPR39 | |
| SCHEMBL16647952 | 0.73 | MPL (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1883632-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2008-02-06 | — | — | EP | disclosed |
| WO-2006116563-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241296-A1 | Acute, inflammatory or neuropathic pain and inflammatory diseases such as asthma, rheumatoid arthritis, inflammatory bowel disorders, urinary incontinence, and psoriasis; e.g. 5-chloro-8-((6-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)-1,2,3,4-tetrahydronaphthalen-2-ol | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241296-A1 | Acute, inflammatory or neuropathic pain and inflammatory diseases such as asthma, rheumatoid arthritis, inflammatory bowel disorders, urinary incontinence, and psoriasis; e.g. 5-chloro-8-((6-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)-1,2,3,4-tetrahydronaphthalen-2-ol | TRPV1, HRH2, TRPA1 | LIPC 3707/4885LIPG 593/4885CRHR1 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.